Annual report pursuant to Section 13 and 15(d)

Recent Developments, Liquidity and Management???s Plans (Details Narrative)

v3.23.1
Recent Developments, Liquidity and Management’s Plans (Details Narrative) - USD ($)
 12 Months Ended
Apr. 16, 2022
Apr. 16, 2021
Apr. 16, 2021
Dec. 31, 2022
Dec. 31, 2021
Aug. 17, 2022
Dec. 31, 2020
Mar. 23, 2020
Goodwill       $ 10,498,539 $ 10,498,539      
Fair market value price per share           $ 4.25    
Cash on hand       749,090 555,967      
Marketable securities       4,086,902 11,003,071      
Loss from operations       15,197,336 29,889,045      
Working capital       2,632,796        
Stockholders' equity       14,695,056 23,647,174   $ (5,257,032)  
Accumulated deficit       93,758,904 78,561,568      
Net cash provided by operating activities       12,270,068 19,516,475      
Net loss       15,197,336 29,889,045      
Non cash share based compensation       695,191      
Increase in trade and other payables       1,686,595 (4,268,961)      
Decrease in prepaid expense       $ 540,560        
Restricted Stock Units (RSUs) [Member]                
Vested restricted stock unit       54,207        
Non cash share based compensation   $ 979,758            
Contribution Agreement [Member] | Premas Biotech PVT Ltd [Member]                
Amount owed on investments         1,500,000      
Payments to investments         $ 1,200,000      
Merger Agreement [Member]                
Issuance of post reverse stock split     28,553,307          
Exchange ratio percentage     77.05%          
Percentage of common stock 49.68%              
Merger Agreement [Member] | Pre-funded Warrants [Member]                
Warrants to purchase   986,486 986,486          
Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member]                
Acquired membership interests, percentage               100.00%
Pre Merger [Member] | Merger Agreement [Member]                
Business acquisition description     Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger Company Common Stock held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger          
Akers Biosciences, Inc [Member]                
Goodwill   $ 10,498,539 $ 10,498,539          
Pre market capitalization   42,477,346 42,477,346          
Tangible asset   $ 31,978,807 $ 31,978,807          
Common shares outstanding     8,335,627          
Akers Biosciences, Inc [Member] | Restricted Stock Units (RSUs) [Member]                
Vested restricted stock unit     263,026          
Fair market value price per share   $ 4.94 $ 4.94